{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "28301379",
  "DateCompleted": {
    "Year": "2017",
    "Month": "11",
    "Day": "16"
  },
  "DateRevised": {
    "Year": "2018",
    "Month": "12",
    "Day": "02"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1097/CAD.0000000000000476"
    ],
    "Journal": {
      "ISSN": "1473-5741",
      "JournalIssue": {
        "Volume": "28",
        "Issue": "4",
        "PubDate": {
          "Year": "2017",
          "Month": "Apr"
        }
      },
      "Title": "Anti-cancer drugs",
      "ISOAbbreviation": "Anticancer Drugs"
    },
    "ArticleTitle": "Hypothesis: ROBOPHERA, a phosphatase and tensin homolog-targeted antineoplastic therapy.",
    "Pagination": {
      "StartPage": "369",
      "EndPage": "375",
      "MedlinePgn": "369-375"
    },
    "Abstract": {
      "AbstractText": [
        "Phosphatase and tensin homolog (PTEN) is a protein that regulates cellular response to growth/antigrowth signals, cell survival, apoptosis, proliferation, angiogenesis, and cellular migration. Impairments in these processes are the main hallmarks of cancer, and reduced expression, activity, or stability of PTEN are among the most common etiologies of diverse types of sporadic cancers. Rosiglitazone (RO), bortezomib (BO), phosphatidylserine (PH), ethanol (E), and radiotherapy (RA) (ROBOPHERA) stimulate the expression and increase the activity of PTEN. Here, it is hypothesized that the synergistic effects of these medications on cancerous cells may stimulate differentiation of cancer stem cells toward non-stem-cancer cells, hinder progression and metastasis of the cancer, sensitize cancerous cells to antineoplastic therapies, and increase the efficacy and the rate of success of current treatments."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Shiraz School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran."
          }
        ],
        "LastName": "Azimi",
        "ForeName": "Arsalan",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Azimi",
        "ForeName": "Arian",
        "Initials": "A"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Anticancer Drugs",
    "NlmUniqueID": "9100823",
    "ISSNLinking": "0959-4973"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Phosphatidylserines"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Thiazolidinediones"
    },
    {
      "RegistryNumber": "05V02F2KDG",
      "NameOfSubstance": "Rosiglitazone"
    },
    {
      "RegistryNumber": "3K9958V90M",
      "NameOfSubstance": "Ethanol"
    },
    {
      "RegistryNumber": "69G8BD63PP",
      "NameOfSubstance": "Bortezomib"
    },
    {
      "RegistryNumber": "EC 3.1.3.67",
      "NameOfSubstance": "PTEN Phosphohydrolase"
    },
    {
      "RegistryNumber": "EC 3.1.3.67",
      "NameOfSubstance": "PTEN protein, human"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Antineoplastic Combined Chemotherapy Protocols"
    },
    {
      "QualifierName": [
        "administration & dosage"
      ],
      "DescriptorName": "Bortezomib"
    },
    {
      "QualifierName": [
        "drug effects",
        "radiation effects"
      ],
      "DescriptorName": "Cell Differentiation"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Chemoradiotherapy"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Synergism"
    },
    {
      "QualifierName": [
        "administration & dosage"
      ],
      "DescriptorName": "Ethanol"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Molecular Targeted Therapy"
    },
    {
      "QualifierName": [
        "drug therapy",
        "enzymology",
        "pathology",
        "radiotherapy"
      ],
      "DescriptorName": "Neoplasms"
    },
    {
      "QualifierName": [
        "drug effects",
        "radiation effects"
      ],
      "DescriptorName": "Neoplastic Stem Cells"
    },
    {
      "QualifierName": [
        "metabolism"
      ],
      "DescriptorName": "PTEN Phosphohydrolase"
    },
    {
      "QualifierName": [
        "administration & dosage"
      ],
      "DescriptorName": "Phosphatidylserines"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Rosiglitazone"
    },
    {
      "QualifierName": [
        "administration & dosage"
      ],
      "DescriptorName": "Thiazolidinediones"
    }
  ]
}